Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week.
Animals
Anticoagulants
/ therapeutic use
Aortic Valve
/ surgery
Cardiology
/ standards
Cattle
Fibrinolytic Agents
/ therapeutic use
Heart Valve Prosthesis
Hemodynamics
Hemorrhage
/ prevention & control
Humans
Platelet Aggregation Inhibitors
/ therapeutic use
Postoperative Complications
/ prevention & control
Practice Guidelines as Topic
Prosthesis Design
Risk Factors
Stents
Stroke
/ etiology
Swine
Thromboembolism
Thrombosis
/ prevention & control
Transcatheter Aortic Valve Replacement
/ adverse effects
Transplantation, Heterologous
Treatment Outcome
United States
TAVR
anticoagulation
aortic stenosis
bleeding
direct oral anticoagulants
transcatheter aortic valve replacement
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
22 10 2019
22 10 2019
Historique:
received:
22
07
2019
revised:
26
08
2019
accepted:
27
08
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
2
6
2020
Statut:
ppublish
Résumé
A large amount of evidence supports the widespread use of transcatheter aortic valve replacement (TAVR) among patients who are at low to intermediate risk for surgery. However, several controversies exist about the optimal antithrombotic regimen to use in these patients. On the one hand, concerns about ischemic stroke, subclinical leaflet thrombosis, valve thrombosis, and long-term durability suggest the need for a stronger antithrombotic regimen to ensure a better patient and valve outcome. On the other hand, the high bleeding risk of this population and the current lack of strong evidence in favor of a more aggressive antithrombotic strategy require caution. This review analyzes the rationale of antithrombotic therapy in TAVR illustrating the present scenario and future perspectives.
Identifiants
pubmed: 31623768
pii: S0735-1097(19)37513-8
doi: 10.1016/j.jacc.2019.08.1032
pii:
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Types de publication
Comparative Study
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2088-2101Informations de copyright
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.